Download Image
    
Share
  
Post
Plitidepsin for COVID-19
2 studies with 163 patients
Hospital Icon Control
Hospital Icon Plitidepsin Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Plitidepsin studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -16% Mortality -16% RCTs -16% RCT mortality -16% Late -16% Favorsplitidepsin Favorscontrol
Dec 2
2024
 PharmaMar, NCT05705167 A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care
36% higher mortality (p=1). RCT 37 hospitalized immunocompromised patients, showing no significant benefit with plitidepsin treatment.
Aug 26
2024
 Landete et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae227 A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
1% lower mortality (p=1). RCT with 205 hospitalized moderate COVID-19 patients showing a trend towards faster time to sustained withdrawal of oxygen supplementation with plitidepsin treatment (1.5 mg/day or 2.5 mg/day for 3 days) compared to standard of care. The ..